In vitro activity of currently available drugs against SARS-CoV-2

In vitro activity of currently available drugs against SARS-CoV-2

The global health emergency caused by the SARS-CoV-2 has highlighted the need for treatments to be administered immediately to people infected with the virus. For this reason, the consortium formed by IrsiCaixa, the Barcelona Supercomputing Center (BSC) and the Animal Health Research Centre of the Agrifood Research and Technology Institute (IRTA-CReSA), with the support of the pharmaceutical company Grifols, is publishing real-time open-access results of in vitro experiments against SARS-CoV-2 carried out using currently available, and thus safe, drugs. Researchers made the decision in order to help with coronavirus clinical trial design, identify effective drug combinations and propose possible therapies.

To ensure access by the scientific and medical community, data are published as soon as they are generated on IrsiCaixa’s website and on an open-access preprint server.

Here you can download the reports generated to date.

Search for SARS-CoV-2 inhibitors in currently approved drugs to tackle COVID-19 pandemia - bioRxiv, April 24, 2020 

SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design for COVID19 Immune Studies and Vaccine Development - Vaccines, August 6, 2020

Pre-clinical search of SARS-CoV-2 inhibitors and their combinations in approved drugs to tackle COVID-19 pandemic - bioRxiv, October 20, 2020


Subscriu-te a la newsletter

Back to Top
Irsi Caixa

Impulsat per:

Fundació 'La Caixa' Generalitat de Catalunya - Departament de Salut


HR Excellence in Research

Membre de:


Amb la col·laboració de: